(VVOS) Vivos Therapeutics, Inc. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(VVOS) Vivos Therapeutics, Inc. Complete Analysis Pack
Unlock Strategic Clarity
This Vivos Therapeutics, Inc. 4P's Marketing Mix Analysis summarizes the product (oral appliance therapy for sleep-disordered breathing), its pricing, distribution channels, and promotional strategy in a concise, ready-to-use format; the page shows a real preview/sample of the report so you can assess content and style—purchase the full version to unlock the complete analysis.
Product
Vivos System
The Vivos System is Vivos Therapeutics’ flagship therapy for adults with dentofacial abnormalities, obstructive sleep apnea, and snoring. It is positioned as non-invasive, non-surgical, and pharmaceutical-free, targeting an estimated 936 million adults worldwide with mild to severe OSA. As the company’s core commercial product, it carries the main clinical value proposition and drives most of the brand’s market story.
VivoScore Program
VivoScore Program is Vivos Therapeutics, Inc.’s screening and home sleep-testing service for adults and children. It helps identify sleep-disordered breathing and support patient qualification, while extending Company Name from therapy into diagnostics. That matters in a market where untreated sleep apnea affects about 1 billion people worldwide.
Airway-focused care
Vivos Therapeutics, Inc.’s airway-focused care targets airway and jaw-related drivers of sleep problems, aiming to address underlying dentofacial conditions rather than just symptoms. That makes it different from standard CPAP-centered care, which mainly manages airflow during sleep instead of correcting anatomy. This product angle supports a more cause-based treatment story in a market where sleep apnea affects an estimated 1 billion adults worldwide.
Licensed-provider use
Vivos Therapeutics, Inc. sells this system through licensed medical professionals, mainly general dentists, so it fits a provider-led model rather than direct consumer self-use. That makes it a clinical treatment platform, designed for office workflows, patient screening, and follow-up care.
In 2025, this channel focus supports higher treatment control and stronger professional trust, since the end user is the clinician, not the patient. It also keeps the product tied to medical decision-making and in-office adoption.
- Sold only through licensed providers
- Built for dental clinical workflows
- Targets general dentists first
U.S.-Canada portfolio
Vivos Therapeutics, Inc.’s U.S.-Canada portfolio is commercially available in two markets, giving the company a cross-border base for treatment devices and testing services. That mix helps patients start care and keep using Vivos Therapeutics, Inc.’s products over time, which supports repeat revenue and broader access.
- Two-country commercial reach
- Devices plus testing services
- Supports recurring use
Vivos Targets a Huge Sleep Apnea Market with Non-Invasive Care
Vivos Therapeutics, Inc.’s Product is led by the Vivos System and VivoScore Program, pairing airway-focused therapy with screening and home sleep testing. In 2025, the model stayed provider-led, sold through licensed dentists in the U.S. and Canada. The core appeal is non-invasive care for adults with OSA and snoring, a market tied to about 936 million adults worldwide.
| Metric | Data |
|---|---|
| Main product | Vivos System |
| Adjacency | VivoScore |
| Channel | Licensed providers |
| Markets | U.S. and Canada |
| Market size | 936 million adults |
What is included in the product
Detailed Word Document
A concise, company-specific review of Vivos Therapeutics, Inc.’s Product, Price, Place, and Promotion strategy, grounded in real market positioning.
Editable Excel File
Condenses Vivos Therapeutics’ 4Ps into a quick, practical snapshot that eases analysis and speeds decision-making.
Reference Sources
Lists primary, reputable sources validating market sizing, pricing, and competitive assumptions for Vivos Therapeutics, speeding due diligence and verifiable decision-making.
Place
United States
The United States is Vivos Therapeutics, Inc.'s main operating market, with the Vivos System sold nationwide through dentists and other clinical channels. That keeps distribution tied to diagnosed demand, not mass retail. With a U.S. population of about 335 million in 2025, the addressable base is large, but access still depends on provider adoption.
Canada
Vivos Therapeutics, Inc. also serves Canada, giving it a cross-border North American reach into a market of about 41.5 million people in 2025.
Distribution stays focused on licensed healthcare providers, which fits a controlled, clinical sales model for oral appliance therapy.
That setup helps Vivos Therapeutics, Inc. reach Canadian patients through professionals rather than mass retail channels.
General dentists
General dentists are Vivos Therapeutics, Inc.'s key distribution endpoint, because they spot and manage airway-related cases where treatment starts. In FY2025, this channel stayed central to patient acquisition and treatment delivery, since the model depends on dentists referring, fitting, and monitoring care. That makes the practice base the real route to market, not direct consumer sales.
Direct provider sales
Vivos Therapeutics, Inc. uses direct provider sales to place its products with licensed medical professionals, not mass retail channels. That setup supports training, clinical oversight, and case-based use, which fits the company’s medical positioning and helps keep distribution tied to patient care.
- Sold through licensed providers
- Supports clinician training
- Improves oversight and fit
- Matches medical-use distribution
Highlands Ranch HQ
Vivos Therapeutics, Inc. is headquartered in Highlands Ranch, Colorado, and uses that base to centralize corporate operations. That setup supports sales, customer support, and administration in one place, which can help keep coordination tight and overhead lean. As a public company, Vivos Therapeutics, Inc. reported $14.1 million in revenue for 2024 and ended 2024 with $9.8 million in cash and equivalents.
- HQ: Highlands Ranch, Colorado
- Centralized corporate operations
- Supports sales, support, admin
- Public filing data: 2024 revenue $14.1 million
Vivos’ Reach: U.S. and Canada Through Dental Channels
Vivos Therapeutics, Inc. sells mainly in the United States and Canada through licensed dentists and clinical providers, not mass retail. That keeps Place tightly linked to diagnosis and treatment. The U.S. base is about 335 million people in 2025, and Canada about 41.5 million.
| Market | 2025 size | Route |
|---|---|---|
| United States | 335M | Dentists |
| Canada | 41.5M | Clinical providers |
Full Version Awaits
Vivos Therapeutics, Inc. Reference Sources
The preview shown here is the actual document you’ll receive instantly after purchase—no surprises; this Vivos Therapeutics, Inc. 4P’s Marketing Mix analysis is the full, editable file you’ll download immediately after checkout, ready to use for strategy or due diligence.
Promotion
Provider education
Provider education is central for Vivos Therapeutics, Inc. because dentists must learn airway-focused therapy, screening, and treatment workflows before they can adopt it. In a specialized medtech market, the sales motion depends on clinical training, not just promotion, so each educated provider can expand patient access and strengthen case acceptance.
Clinical differentiation
Vivos Therapeutics, Inc. pushes clinical differentiation by stressing its non-invasive, non-surgical, and drug-free approach, which helps set it apart from CPAP and surgery. That message matters because sleep-disordered breathing affects millions of adults in the U.S., and Vivos positions its therapy as a less disruptive option. Clinical proof is the core sell: the brand uses outcomes and physician-led care to back the claim.
VivoScore awareness
VivoScore awareness widens Vivos Therapeutics, Inc.'s funnel by flagging sleep-disordered breathing early; an estimated 936 million adults aged 30-69 had obstructive sleep apnea worldwide.
Home sleep testing can turn screening into diagnosis faster, which helps move patients toward treatment adoption.
That also broadens awareness beyond appliance therapy alone and positions Vivos Therapeutics, Inc. as a first-step entry point.
Digital outreach
Digital outreach is a low-cost, high-reach promo channel for Vivos Therapeutics, Inc., especially for a niche medical technology company. Web content, press releases, and investor updates help explain its therapy platform to providers and keep shareholders informed. These channels matter most when a company needs trust, education, and visibility at the same time.
- Reaches providers and investors fast
- Supports product education online
- Fits niche med-tech promotion
Training events
Training events—webinars, conferences, and in-practice sessions—help Vivos Therapeutics, Inc. explain protocols, outcomes, and rollout steps, which can speed adoption in a provider-led sales model. They matter more when the product needs clinical buy-in, not just a marketing pitch.
Supports clinician education and trust
Clarifies use, outcomes, and setup
Fits provider-led selling
Provider Education Drives Vivos’ Non-Invasive Sleep Apnea Adoption
Vivos Therapeutics, Inc. promotes through provider education, because its airway therapy depends on dentists learning screening and treatment workflows. Its message stays clear: non-invasive, non-surgical, drug-free care versus CPAP or surgery.
Awareness tools like VivoScore and home sleep tests widen the funnel; 936 million adults aged 30-69 had obstructive sleep apnea worldwide.
Web content, press releases, webinars, and in-practice training keep adoption tied to proof, trust, and clinical use.
| Promo lever | Value |
|---|---|
| Global OSA market | 936M adults |
| Core channel | Provider education |
Price
Case-based pricing
Case-based pricing fits Vivos Therapeutics, Inc.'s medical-device-and-service model, because fees are set by each treatment case, not a shelf price. It lets pricing reflect patient needs, case complexity, and clinician time, which is common in dental sleep care where treatment paths vary. That keeps revenue tied to delivered care, not unit volume.
Provider-level pricing
Vivos Therapeutics, Inc. uses provider-level pricing, so licensed professionals buy devices and related services at the practice level, not as direct-to-consumer retail. That makes its model B2B-style, with pricing tied to clinic adoption, training, and patient volume. Public materials do not show a standard list price, so the real price is set through practitioner contracts and workflow packages.
Bundle structure
Vivos Therapeutics, Inc. can price therapy and screening separately or bundle them with devices, training, and diagnostics. Bundles lift total case value and make adoption easier for practices because one package lowers friction in both clinical setup and patient enrollment. In practice, this supports higher ticket sales and smoother rollout across providers.
Insurance sensitivity
Vivos Therapeutics, Inc. pricing is highly insurance sensitive because sleep-apnea uptake depends on reimbursement and what patients must pay out of pocket. When coverage is weak or deductibles are high, even clinically useful therapy can face slower adoption, so pricing has to stay aligned with healthcare economics.
- Coverage drives demand.
- Patient cost affects conversion.
- Reimbursement shapes pricing power.
Practice-specific
Vivos Therapeutics, Inc. uses practice-specific pricing, so there is no single consumer MSRP. Each dental or sleep practice sets fees by treatment plan, which keeps pricing flexible in professional channels and lets the Company fit local reimbursement and case complexity.
- Practice-set fees, not retail MSRP
- Pricing varies by treatment plan
- Better fit for professional channels
Vivos Pricing Is Case-Based, Not Public
Vivos Therapeutics, Inc. has no public MSRP; pricing is practice-set and case-based, so fees vary by treatment plan, diagnostics, and clinician time. Bundles that include therapy, devices, and training lift case value and help clinics adopt faster. Reimbursement still drives demand, so out-of-pocket cost can slow conversion.
| Price cue | Impact |
|---|---|
| No public list price | Contract-based |
| Case-based fees | Flexible pricing |
| Insurance sensitivity | Adoption risk |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.